HLA-E
-
Official Full Name
major histocompatibility complex, class I, E -
Overview
HLA-E belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. HLA-E binds a restricted subset of peptides derived from the leader peptides of other class I molecules. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. -
Synonyms
HLA-E;major histocompatibility complex, class I, E;HLA class I histocompatibility antigen, alpha chain E;MHC HLA-E alpha-1;lymphocyte antigen;MHC HLA-E alpha-2.1;MHC class I antigen E;HLA class I histocompatibility antigen, E alpha chain;MHC;QA1;EA1.2;EA2.1;HLA-6.2;DKFZp686P19218
Recombinant Proteins
- Human
- E.coli
- HEK293
- Insect Cells
- Mammalian Cells
- In Vitro Cell Free System
- His
- Non
- Avi
- Fc
- Myc
- Flag
- GST
- SUMO
| Cat.# | Product name | Source (Host) | Species | Tag | Protein Length | Price |
|---|---|---|---|---|---|---|
| HLA-E-3399H | Recombinant Human HLA-E protein, His-tagged | E.coli | Human | His | 23-303 aa | |
| HLA-E-1746H | Recombinant Human HLA-E protein, His-tagged | E.coli | Human | His | Gly22~Leu358 |
|
| HLA-E-800HCL | Recombinant Human HLA-E cell lysate | Human | Non |
|
||
| HLA-E-038H | Recombinant Human HLA-E protein, His-Avi-tagged | HEK293 | Human | Avi&His | It contains Gly25-Ile305(HLA-E),Ile21-Met119(B2M) and VMAPRTLVL peptide. |
|
| HLA-E-039H | Recombinant Human HLA-E protein, His-Avi-tagged, Biotinylated | HEK293 | Human | Avi&His | It contains Gly25-Ile305(HLA-E),Ile21-Met119(B2M) and VMAPRTLVL peptide. |
|
| HLA-E-040HP | Recombinant Human HLA-E complex Protein (tetramer), His-Avi-tagged, PE-Labeled | HEK293 | Human | Avi&His | Gly25-Ile305(HLA-E*01:03),Ile21-Met119(B2M) and VMAPRTLVL peptide |
|
| HLA-E-1076H | Recombinant Human HLA-E Protein, His (Fc)-Avi-tagged | HEK293 | Human | Avi&Fc&His |
|
|
| HLA-E-1076H-B | Recombinant Human HLA-E Protein Pre-coupled Magnetic Beads | HEK293 | Human |
|
||
| HLA-E-2276H | Recombinant Human HLA-E protein, His&Myc-tagged | Insect Cells | Human | His&Myc | 22-305aa |
|
| HLA-E-268HFL | Recombinant Full Length Human HLA-E Protein, C-Flag-tagged | Mammalian Cells | Human | Flag | Full L. |
|
| HLA-E-3602HF | Recombinant Full Length Human HLA-E Protein, GST-tagged | In Vitro Cell Free System | Human | GST | Full L. 358 amino acids |
|
| HLA-E-3872H | Recombinant Human HLA-E protein, His-SUMO-tagged | E.coli | Human | His&SUMO | 22-305aa |
|
Involved Pathway
HLA-E involved in several pathways and played different roles in them. We selected most pathways HLA-E participated on our site, such as Endocytosis,Phagosome,Cell adhesion molecules (CAMs), which may be useful for your reference. Also, other proteins which involved in the same pathway with HLA-E were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Epstein-Barr virus infection | PIK3CA,POLR2G,FCER2,PSMD1,GTF2E2,CD19,TAB2,PTMA,PLCG1,HLA-DRB5 |
| Viral carcinogenesis | GRB2,Casp3,GSN,PIK3R5,ACTN1,HDAC3,KAT2A,HDAC4,HIST1H2BJ,CREB3L3 |
| Antigen processing and presentation | KIR2DL1,HLA-DRB5,CALR,B2M,RFX5,HLA-F,NFYC,HLA-DRB3,KIR2DS2,CANX |
| Allograft rejection | FASLG,CD40,CD80,CD40LG,HLA-C,HLA-G,CD86,Fasl,H2-Q10,IL12A |
| Type I diabetes mellitus | HLA-G,Il2,FASLG,HLA-DQA2,HLA-DRB5,CPE,IL12A,CD80,Fasl,HLA-DOA |
| Viral myocarditis | H2-Q10,HLA-DRB4,ICAM1,HLA-DPB1,CD40,Casp3,SGCA,HLA-DMB,RAC1,HLA-B |
| Phagosome | CALRL2,ATP6V0D2,STX18,ITGAV,Cd209g,ITGB3,TLR4BB,RAB5AB,SEC22BA,TUBA8L4 |
| ne thyroid disease | H2-AB1,IFNA13,HLA-DMA,HLA-G,HLA-DRA,FASLG,HLA-DMB,HLA-DQA2,IFNA8,HLA-A |
| Cell adhesion molecules (CAMs) | CD8A,JAM3B,CLDN7A,MAG,SELE,MHC2DEB,HLA-DQA2,ITGB2,CLDN16,CLDN5 |
Protein Function
HLA-E has several biochemical functions, for example, MHC class I protein binding,beta-2-microglobulin binding,natural killer cell lectin-like receptor binding. Some of the functions are cooperated with other proteins, some of the functions could acted by HLA-E itself. We selected most functions HLA-E had, and list some proteins which have the same functions with HLA-E. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| receptor binding | PVRL1,Itga10&Itgb1,WNT4A,F2R,ABL2,MAG,WNT2BB,APOL2,FGF1B,ADM |
| natural killer cell lectin-like receptor binding | RAET1D,Mill2,RAET1G,ULBP3,MICA,ULBP2,RAET1L,Raet1c,Raet1a,ULBP1 |
| peptide antigen binding | MHC1ZBA,CD209,HLA-F,MHC1ZDA,CLEC4M,HLA-G,HLA-DRA,HLA-DQB1,DHCR24,TAPBP |
| MHC class I protein binding | Pilrb1,BCAP31,CD8A,ATP5B,ATP5A1,TUBB4B,TUBB,VCP,PILRB,DERL1 |
| beta-2-microglobulin binding | HLA-A,CD1d1,CD1E,H2-Q10,CD1B,HFE,CD1C,CD1D2,CD1D,FCGRT |
Interacting Protein
HLA-E has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with HLA-E here. Most of them are supplied by our site. Hope this information will be useful for your research of HLA-E.
YPMT1.25Ac;TRAPPC2;fusA;lldD1;q5ni35_fratt;q7chg5_yerpe;proW;q7ckk6_yerpe;deoB;ptsG;y2173_bacan;q81wx2_bacan;dacF;q81z87_bacan;q8cl08_yerpe;sfcA2;leuB;PPP1R16A
Resources
Research Area
Related Services
Related Products
References
- Cheung, PFY; Yip, CW; et al. Granulin-Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity. CANCER IMMUNOLOGY RESEARCH 2:1209-1219(2014).
- Ravindranath, MH; Terasaki, PI; et al. Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg. CLINICAL AND EXPERIMENTAL IMMUNOLOGY 178:154-177(2014).
